Testing eye drops to improve blood flow in diabetic and glaucoma patients

Plain-English translation of NCT07354477 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This is a small pilot study testing whether QLS-111 ophthalmic solution can help improve blood flow in the back of the eye. The study involves people with diabetic retinopathy (eye damage from diabetes) or glaucoma (high pressure in the eye), and researchers want to see if this new eye drop medication can widen blood vessels and improve circulation to the eye.

Diabetic eye disease and glaucoma can both damage vision by affecting blood flow to sensitive parts of the eye. This medication is being tested to see if it might help restore or improve that blood flow, which could potentially slow vision loss or help preserve eyesight.

Do you qualify?

You likely qualify if…

you have been diagnosed with mild to moderate open-angle glaucoma, normal tension glaucoma, or stable diabetic retinopathy in at least one eye
your vision, when corrected with glasses or contacts, is 20/200 or better in each eye
you are willing and able to follow the study instructions and give informed consent
you are able to come to four study visits over about two weeks

You likely don't qualify if…

you are currently taking more than one eye drop medication to control eye pressure (except if you've had laser or surgical treatment at least 3 months before)
you have used beta-blocker eye drops like timolol within the past 3 months
you are not reliable about taking your current eye medications as prescribed
you have severe eye disease beyond glaucoma or diabetic retinopathy that would need treatment during the study
you have significant kidney disease (Stage 3 or higher) or serious uncontrolled heart, lung, or blood pressure problems

What participation looks like

You would visit the clinic four times over about two weeks. At your first visit, you'll have baseline eye exams and testing. Then you'll use the eye drops twice daily (12 hours apart) in both eyes—starting with a weaker concentration for the first week, then a stronger concentration for the second week. During two more visits during treatment, the study team will measure how your eyes are responding. Finally, you'll have a follow-up visit after you stop using the drops to see if there are any lasting effects.

AI-generated summary from trial data · Jul 13, 2026 · Not medical advice

Trial locations(1 site)

United States

Stanford University, Dept. of Ophthalmology, Palo Alto, California